These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 14729755)

  • 1. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
    Li C; Nicolau DP; Lister PD; Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 2004 Feb; 53(2):297-304. PubMed ID: 14729755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.
    Lister PD; Gardner VM; Sanders CC
    Antimicrob Agents Chemother; 1999 Apr; 43(4):882-9. PubMed ID: 10103195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Fujimura S; Takane H; Nakano Y; Watanabe A
    J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
    [No Abstract]   [Full Text] [Related]  

  • 6. Timentin (ticarcillin/clavulanic acid): lack of antagonism in an in vitro kinetic model, against bacteria producing inducible class-1 beta-lactamase.
    Slocombe B; Cooper CE; Masters PJ; Warrack JD
    J Chemother; 1989 Jul; 1(4 Suppl):353-4. PubMed ID: 16312436
    [No Abstract]   [Full Text] [Related]  

  • 7. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sensitivity of Pseudomonas aeruginosa to beta-lactam antibiotics and effects of beta-lactamases].
    Avril JL; Cayla AM; Guist'hau O; Moillo-Batt A
    Pathol Biol (Paris); 1983 Jun; 31(6):471-5. PubMed ID: 6410345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro activity of beta-lactam agents and beta-lactamase inhibitors in clinical isolates of Acinetobacter baumannii].
    López-Hernández S; Alarcón T; Delgado T; de Las Cuevas MC; López-Brea M
    Rev Esp Quimioter; 1999 Jun; 12(2):140-3. PubMed ID: 10562675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibilities of 97 strains of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.
    Ismaeel NA
    Microbios; 1997; 91(367):97-103. PubMed ID: 9467924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran.
    Japoni A; Alborzi A; Kalani M; Nasiri J; Hayati M; Farshad S
    Burns; 2006 May; 32(3):343-7. PubMed ID: 16527415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characterization of the resistance to combinations of beta lactams and inhibitors of beta-lactamases in Escherichia coli. Effect of the type and amount of beta-lactamase production].
    del Mar Pérez-Moreno M; Pous-Miralles G; Romera-Sastre G; Panisello-Bertomeu JM; Jardí-Baiges AM; Zarazoga-López J
    Enferm Infecc Microbiol Clin; 1997 Nov; 15(9):477-81. PubMed ID: 9527373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral beta-lactamase inhibitor combinations for clinical use.
    Manzella JP
    Am Fam Physician; 1995 May; 51(7):1695-8. PubMed ID: 7754928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ticarcillin and ticarcillin/clavulanic acid on the in-vitro activity of human granulocytes against beta-lactamase-producing Klebsiella pneumoniae.
    Cuffini AM; de Renzi G; Tullio V; Paizis G; Carlone NA
    Int J Tissue React; 1995; 17(5-6):199-203. PubMed ID: 8835630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study.
    Cavallo JD; Hocquet D; Plesiat P; Fabre R; Roussel-Delvallez M;
    J Antimicrob Chemother; 2007 May; 59(5):1021-4. PubMed ID: 17412726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
    Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
    Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.